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Abstract: 
Trans-10,cis-12 conjugated linoleic acid (CLA) has previously been shown to be the CLA 
isomer responsible for CLA-induced reductions in body fat in animal models, and we have 
shown that this isomer, but not the cis-9,trans-11 CLA isomer, specifically decreased 
triglyceride (TG) accumulation in primary human adiopcytes in vitro. Here we investigated the 
mechanism behind the isomer-specific, CLA-mediated reduction in TG accumulation in 
differentiating human preadipocytes. Trans-10,cis-12 CLA decreased insulin-stimulated glucose 
uptake and oxidation, and reduced insulin-dependent glucose transporter 4 gene expression. 
Furthermore, trans-10,cis-12 CLA reduced oleic acid uptake and oxidation when compared with 
all other treatments. In parallel to CLA’s effects on metabolism, trans-10,cis-12 CLA decreased, 
whereas cis-9,trans-11 CLA increased, the expression of peroxisome proliferator-activated 
receptor γ (PPARγ) and several of its downstream target genes when compared with vehicle 
controls. Transient transfections demonstrated that both CLA isomers antagonized ligand-
dependent activation of PPARγ. Collectively, trans-10,cis-12, but not cis-9, trans-11, CLA 
decreased glucose and lipid uptake and oxidation and preadipocyte differentiation by altering 
preadipocyte gene transcription in a manner that appeared to be due, in part, to decreased PPARγ 
expression. 
 
Article: 
Conjugated linoleic acid (CLA) refers to a group of geometric and positional dienoic isomers of 
linoleic acid (LA) [18:2(n-6)]. The two predominant isomers of CLA found in food and 
commercial preparations are cis-9,trans-11 CLA and trans-10,cis-12 CLA. CLA is found in 
ruminant meats, pasteurized cheeses, and dairy products, and therefore is a natural part of the 
diet. CLA has been extensively studied due to its potentially beneficial effects on carcinogenesis 
(1–3), diabetes (4, 5), atherosclerosis (6, 7), immune function (8–10), and body composition (11–
16). Collectively, animal studies demonstrate that dietary intake of a crude mixture of CLA 
isomers prevents the development of obesity (11–16). Furthermore, the trans-10,cis-12 isomer of 
CLA is the isoform responsible for decreasing fat mass in animals and triglyceride (TG) content 
in murine and human adipocytes in vitro (17, 18). However, proposed mechanisms by which 
CLA exerts its antiobesity effects are diverse and often conflicting. For example, Satory and 
Smith (19) found paradoxically that postconfluent cultures of differentiating 3T3-L1 
preadipocytes treated with a crude mixture of CLA isomers had greater rates of lipogenesis and 
increased levels of TG compared with vehicle controls, yet CLA inhibited proliferation in 
preconfluent cultures. This CLA-mediated inhibition of proliferation was confirmed by Brodie et 
al. (20), yet they found that a crude mixture of CLA isomers decreased TG content and/or 
markers of adipocyte differentiation in 3T3-L1 preadipocytes. These results suggest that CLA 
attenuates adipocyte differentiation, but other reports refute this claim, demonstrating that the 
expression of the key adipogenic transcription factors, peroxisome proliferator-activated receptor 
γ (PPARγ) and CAAT/enhancer binding protein α (C/EBPα), is unaffected by CLA in 
differentiating murine preadipocytes (21). 
 
In addition to CLA’s potential role in influencing preadipocyte proliferation and differentiation, 
CLA has been shown to alter lipid metabolism, which may help explain its TG-lowering actions. 
For example, the trans-10,cis-12 isomer of CLA has been shown to inhibit fatty acid desaturation 
by decreasing the activity or mRNA levels of Δ9-, Δ6-, and Δ5-desaturases in murine 
preadipocytes or hepatic microsomes, human breast cancer cells, and human hepatocytes (21–
25). This trans-10,cis-12 CLA-mediated reduction in fatty acid desaturation results in a 
decreased monounsaturated fatty acid (MUFA) to saturated fatty acid (SFA) ratio (21, 23). It has 
been postulated that without adequate levels of the MUFA oleate, a preferential substrate for TG 
synthesis (26), TG levels are diminished. Another potential mechanism by which CLA mediates 
its antiobesity effects is by increasing energy expenditure and fatty acid oxidation (27–35). 
Collectively, animal studies clearly demonstrate that mixed isomers of CLA can attenuate 
obesity, yet isomer-specific mechanisms by which CLA exerts these effects are conflicting and 
unresolved. In addition, the influence of specific CLA isomers on body fat and adipogenesis in 
humans is unclear (36–44). 
 
PPARs are ligand-activated nuclear hormone receptors that heterodimerize with the retinoid X 
receptor and act to control the expression of genes involved in cellular metabolism and 
differentiation (45, 46). Fatty acids or their metabolites serve as ligand activators for all PPAR 
isoforms (α, γ, and δ/β), yet ligand activation leads to distinct control of downstream target gene 
expression (45–47). For example, activation of PPARα in the liver increases expression of key 
regulatory proteins in the catabolic β- and ω-oxidation pathways (48–50). By contrast, PPARγ is 
the master adipogenic transcription factor and induces anabolic processes such as TG synthesis, 
glucose uptake, and fatty acid uptake by directly or indirectly enhancing the transcription of 
genes encoding proteins such as adipocyte fatty acid binding protein (aP2) (51), insulin-
dependent glucose transporter 4 (GLUT4) (52), lipoprotein lipase (LPL) (53), and the fatty acid 
translocase (CD-36/FAT) (54). The trans-10,cis-12 and the cis-9,trans-11 isomers of CLA have 
been shown to act as potent ligands of PPARα and -δ, whereas activation of PPARγ is minor (4, 
27, 28, 53, 55, 56). It has been suggested that increased β-oxidation (29–31) and energy 
expenditure (27, 32–34) due to activation of PPARα may contribute to the antiadipogenic effect 
of CLA. However, since both isomers are ligands of PPARα, activation of this transcription 
factor does not explain the observed isomer-specific effects of the trans-10,cis-12 isomer. 
Furthermore, a recent report by Peters et al. (35) using PPARα-null mice clearly demonstrated 
that the influence of CLA on body composition is independent of PPARα activation. Since trans-
10,cis-12 CLA is only a weak activator of PPARγ and has been shown to interfere with lipid 
accumulation in adipocytes in vivo and in vitro, we hypothesized that this CLA isomer might be 
a partial agonist of PPARγ, or alternatively may interfere with endogenous agonist production. 
 
In this study, we further characterize the isomer-specific effects of CLA on glucose and lipid 
metabolism in primary human preadipocytes and show the trans-10,cis-12, but not the cis-
9,trans-11, isomer of CLA attenuates glucose and fatty acid uptake and oxidation as well as fatty 
acid incorporation into TG. These processes are known to be increased during adipocyte 
differentiation (57). In parallel, the expression of PPARγ and a number of PPARγ target genes 
are down-regulated by the trans-10,cis-12, but not the cis-9,trans-11, isomer of CLA. Thus, the 
long-term effects of trans-10,cis-12 CLA on glucose and lipid metabolism are likely to be 
mediated by a PPARγ-dependent attenuation of adipocyte-specific gene expression. 
 
MATERIALS AND METHODS 
Materials 
All cell culture ware and scintillation cocktail (ScintiSafe) were purchased from Fisher Scientific 
(Norcross, GA). d-glucose-U-[14C] was purchased from ICN Biochemicals, Inc. (Irvine, CA). 
Deoxy-d-glucose 2-[1,2-3H(N)], [1-14C]oleic acid and Western Lightning Chemiluminescence 
Substrate were purchased from Perkin Elmer Life Science (Boston, MA). One-step reverse 
transcription-polymerase chain reaction (RT-PCR) kit used in semi-quantitative mRNA analysis 
was purchased from Qiagen, Inc. (Valencia, CA). Gene-specific primers for relative RT-PCR 
and all immunoblotting buffers and precast gels were purchased from Invitrogen (Carlsbad, CA), 
and ribosomal 18S competimer technology internal standards and DNA-free were purchased 
from Ambion (Austin, TX). Gene-specific primers for real-time PCR were purchased from DNA 
Technology A/S (Aarhus, Denmark), and the real-time PCR kit was from Applied Biosystems 
(Copenhagen, Denmark). Fetal bovine serum (FBS) was purchased from BioWhittaker 
(Cambrex/Biowhittaker, Walkersville, MD) unless otherwise specified. LA (99% pure) and fatty 
acid standards for gas chromatography (GC) analysis were purchased from Nu-Check-Prep 
(Elysian, MN). Isomers of CLA (+98% pure) were purchased from Matreya (Pleasant Gap, PA). 
Rubber stoppers and an inverted center-well hanging bucket for CO2 assays were purchased 
from Kontes Glass Comp. (Vineland, NJ). All other reagents and chemicals were purchased from 
Sigma Chemical (St. Louis, MO) unless otherwise stated. 
 
Cell culture of human primary preadipocytes 
Isolation and culture of stromal vascular cells from adipose tissue. Abdominal adipose tissue 
was obtained from females with a body mass index (BMI) <30.0 during liposuction or elective 
surgery with consent, or obtained from Zen Bio, Inc. as previously described (18). Approval to 
use adipose tissue obtained from humans was secured from the Institutional Review Board at the 
University of North Carolina at Greensboro. Cells were isolated and cultured as previously 
defined (18). 
 
Induction of cell differentiation. Freshly split stromal vascular (SV) cells were seeded (4 × 104 
cells/cm2) in cell culture plates and allowed to attach for 24 h in proliferation medium. Following 
attachment, cultures were grown for the next 3 days in differentiation medium containing 97% 
DMEM/Ham’s F-10 (1:1, v/v), 30 ml/l FBS, 15 μM HEPES (pH 7.4), 33 μM biotin, 17 μM 
pantothenate, 100 nM human recombinant insulin, 1 μM dexamethasone, 100 U/ml penicillin, 
100 U/ml streptomycin, 25 mg/l fungizone, 0.25 mM isobutylmethylxanthine (IBMX), and 1 μM 
of the thiazolidinedione BRL 49653 (Rosiglitazone from GlaxoSmith-Kline). Thereafter, 
cultures were exposed to adipocyte medium consisting of 97% DMEM/Ham’s F-10 (1:1, v/v), 30 
ml/l FBS, 15 μM HEPES (pH 7.4), 33 μM biotin, 17 μM pantothenate, 100 nM human 
recombinant insulin, 1 μM dexamethasone, 100 U/ml penicillin, 100 U/ml streptomycin, and 25 
mg/l fungizone. Adipocyte media was replaced every 2 days. After 10–12 days under these 
conditions, ~50–80% of the cells had visible lipid droplets. 
 
Fatty acid preparation 
Both isomers of CLA and LA were complexed to fatty acid-free (>98%) bovine serum albumin 
(BSA) at a 4:1 molar ratio using 1 mM BSA stocks, or were dissolved in dimethylsulfoxide 
(DMSO) for the transfection studies. All cultures were continuously treated with varying 
concentrations of fatty acids that were added fresh with each media change (every 2 days). 
 
Lipid staining 
The presence of intracellular lipid was visualized by staining the cultures with oil red O (ORO) 
(58). Cell monolayers were washed twice with Hank’s balanced salt solution (HBSS) and fixed 
for 24 h in 10% formalin, 4% calcium chloride buffer at 4°C. After fixation, cells were washed 
twice with deionized water and stained with 0.3% ORO in isopropanol for 15 min at room 
temperature. Following staining, cells were washed using 20% ethanol and deionized water to 
remove any undissolved stain. Stained adipocytes were visualized under an Olympus IMT-2 
inverted-phase contrast microscope, and photomicrographs were taken of representative fields in 
each well. 
 
[14C]oleic acid incorporation into lipid-soluble and water-soluble cellular fractions 
Cultures were seeded at 4 × 104 cells/cm2 in 12-well culture plates and allowed to differentiate 
for 5 days in the presence of vehicle or fatty acid treatments. On Day 5, cultures were incubated 
in 1 ml of serum-free DMEM basal medium containing 1,000 mg/l d-(+)-glucose ± fatty acids. 
Following a 24 h basal period (Day 6), 20 μl of HBSS containing 12.5 nmol of [1-14C]oleic acid 
(specific activity = 40–60 mCi/mmol) was added to each well, and incubated at 37°C for 2 h (a 
time course study indicated a linear incorporation into lipid and water soluble cellular fractions 
over a 4 h period; data not shown). After 2 h, media containing unincorporated isotope was 
removed, and monolayers were washed 3× with HBSS, and lysed in 0.1% sodium dodecylsulfate 
(SDS) phosphate-buffered saline (PBS). Total lipid and water-soluble fractions were extracted 
and purified using the Bligh and Dyer method (59). Using this method at neutral pH, the lipid 
soluble fraction would predominantly contain [14C]oleic acid esterified into complex lipids. In 
contrast, the water-soluble fraction would likely contain [14C]oleoyl-CoA (i.e., [14C]oleate 
thioesters accumulated prior to β-oxidation) and some products occurring after the partial 
oxidation of [14C]oleate (i.e., [14C]acetyl-CoA, [14C]tricarboxylic acids, and other small 
metabolic intermediates). The partitioned samples were then subjected to liquid scintillation 
counting (Beckman LS 6000; Beckman Instruments, Palo Alto, CA) to determine incorporation 
into the lipid- and water-soluble cellular fractions. Protein concentration of parallel cultures was 
determined using the bicinchoninic acid (BCA) colorimetric assay (Pierce, Rockford, IL) using 
BSA as a control. To control for unincorporated residual [14C]oleic acid, a set of cultures was 
briefly exposed (<30 s) and immediately washed and harvested; the resulting radioactivity was 
subtracted from all experimental results. 
 
[14C]CO2 production from [14C]oleic acid 
Cultures were seeded at 4 × 104 cells/cm2 in 35 mm culture plates and allowed to differentiate for 
5 days in the presence of vehicle or fatty acid treatments. On Day 5, cultures were incubated in 1 
ml of serum-free DMEM basal medium containing 1,000 mg/l d-(+)-glucose in the presence of 
vehicle or fatty acid treatment. On Day 6, 20 μl of HBSS containing 12.5 nmol of [1-14C]oleic 
acid (specific activity = 40–60 mCi/mmol) was added to each plate, and the plate was quickly 
placed in an airtight CO2 collection chamber (60 ml Nalgene jar with a fitted rubber stopper, and 
hanging center-well collection bucket containing What-man filter paper soaked with 50 μl 
benzothonium hydroxide). The CO2 collection chamber was incubated at 37°C for 90 min. (A 
time course study indicated a linear production of [14C]CO2 from [14C]oleic acid over a 4 h 
period; data not shown). Following the 90 min incubation with isotope, the reaction was 
terminated by the addition of 100 μl 0.5 M H2SO4 to the cell monolayer using syringe injection. 
Liberation of CO2 was allowed to proceed for an additional 30 min, and then the center-well 
collection bucket was cut out of the collection chamber and delivered to a liquid scintillation 
vial. Five milliliters of scintillation cocktail was immediately added to each vial, and all samples 
were vortexed and incubated overnight before counting. Production of [14C]CO2 from [14C]oleic 
acid was determined by liquid scintillation counting using a Beckman LS 6000. The addition of 1 
μM WY-14643 or 20 μM Gemfibrozil (potent PPARα agonists) increased [14C]oleic acid 
metabolism into [14C]CO2 by ~100% (data not shown). Protein concentration of parallel cultures 
was determined using the BCA assay. 
 
[14C]oleic acid uptake 
Cultures were seeded at 4 × 104 cells/cm2 in 12-well culture plates and allowed to differentiate 
for 5 days in the presence of fatty acid treatments. On Day 5, cultures were incubated in 1 ml of 
serum-free DMEM basal medium containing 1,000 mg/l d-(+)-glucose in the presence of vehicle 
or fatty acid treatments. On Day 6, culture media was removed and replaced with 1 ml of HBSS 
buffer containing 100 nM human insulin. Afterwards, 20 μl of HBSS containing 6.2 nmol [1-
14C]oleic acid (specific activity = 40–60 mCi/mmol) was added to each well and incubated at 
37°C for 20 min (a time course study indicated a linear increase in radiolabeled oleic acid uptake 
over a 1 h period; data not shown). Uptake was terminated by the addition of an ice-cold stop 
buffer (HBSS supplemented with 2% BSA). Monolayers were carefully washed an additional 2× 
with stop buffer to remove background radioactivity, and lysed in 0.1% SDS-PBS. The total 
cellular lysate was subjected to liquid scintillation counting to determine cellular uptake. Protein 
concentration of parallel cultures was determined using the BCA colorimetric assay. To control 
for unincorporated residual [14C]oleic acid, a set of cultures was briefly exposed to [14C]oleic 
acid (<30 s), and immediately washed and harvested; the resulting radioactivity was subtracted 
from all experimental results. 
 
[14C]CO2 production from [14C]glucose 
Cultures were seeded at 4 × 104 cells/cm2 in 35 mm culture plates and allowed to differentiate for 
5 days in the presence of vehicle or fatty acid treatments. On Day 5, cultures were incubated in 1 
ml of serum-free DMEM basal medium containing 1,000 mg/l d-(+)-glucose and 20 pM human 
insulin in the presence of BSA or fatty acids. On Day 6, culture media was removed and replaced 
with 1 ml of HBSS buffer containing 100 nM human insulin for 10 min. After insulin 
preincubation, 20 μl of HBSS containing 2.2 nmol d-[U-14C]glucose (specific activity = 231 
mCi/mmol) was added to each plate, and the plate was quickly placed in an airtight CO2 
collection chamber (as described for oleic acid oxidation). The CO2 collection chamber was 
incubated at 37°C for 5 h (a time course study indicated a linear increase in radiolabeled CO2 
production from [14C]glucose over an 8 h period; data not shown). Following the 5 h incubation, 
the reaction was terminated by the addition of 100 μl 0.5 M H2SO4 to the cell monolayer by 
syringe injection. Liberation of CO2 was allowed to proceed for an additional 30 min, and then 
the center-well collection bucket was cut out of the collection chamber and delivered to a liquid 
scintillation vial. Five milliliters of scintillation cocktail was immediately added to each vial, and 
all samples were incubated overnight before counting. Production of [14C]CO2 from [14C]glucose 
was determined by liquid scintillation counting as previously described. Protein concentration of 
parallel cultures was determined by the BCA assay. 
 
[3H]2-deoxy-glucose uptake 
Cultures were seeded at 4 × 104 cells/cm2 in 35 mm culture plates and allowed to differentiate for 
10 days in the presence of vehicle or fatty acid treatments. On Day 10, cultures were incubated in 
1 ml of serum-free DMEM basal medium containing 1,000 mg/l d-(+)-glucose and 20 pM human 
insulin in the presence of vehicle or fatty acid treatments. On Day 12, culture media was 
removed and replaced with 1 ml of HBSS buffer containing 100 nM human insulin for 10 min. 
After insulin preincubation, 20 μl of HBSS containing 4 nmol 2-[1,2-3H(N)]deoxy-d-glucose 
(specific activity = 25–50 Ci/mmol) was added to each plate and incubated at 37°C for 90 min (a 
time course study indicated a linear increase in [3H]deoxy-d-glucose uptake over 4 h; data not 
shown). Uptake was terminated by the addition of an ice-cold stop Krebs-Ringer buffer 
supplemented with 25 mM d-(+)-glucose. Monolayers were carefully washed an additional 2× 
with stop buffer to remove background radioactivity, and lysed in a 0.1% SDS-PBS. The total 
cellular lysate was subjected to liquid scintillation counting to determine cellular uptake. Protein 
concentration of parallel cultures was determined by the BCA assay. To control for 
unincorporated residual 2-[1, 2-3H(N)]deoxy-d-glucose, a set of cultures was briefly exposed to 
the isotope (<30 s), and immediately washed and harvested. The resulting radioactivity was 
subtracted from all experimental results. Insulin induced a 3-fold stimulation of glucose uptake 
when compared with noninsulin-stimulated controls (data not shown), and treatment with 5 μM 
cytochalasin B inhibited insulin-stimulated glucose uptake by 90% (data not shown). 
 
Fatty acid extraction and GC analysis 
Cultures were seeded at 4 × 104 cells/cm2 in 35 mm culture plates and allowed to differentiate for 
12 days in the continuous presence of either BSA or 30 μM trans-10,cis-12 CLA. On Day 12, 
total cellular lipids were extracted in chloroform-methanol (2:1, v/v) as previously described 
(60). Neutral and polar lipids were separated using Sep-Pak solid-phase silica cartridges (Waters 
Corp., Milford, MA). The resulting lipid extracts were dried under nitrogen and converted to 
fatty acid methyl esters using 4% HCl-methanol at 60°C for 20 min and analyzed as previously 
described (13). Briefly, fatty acid methyl esters were extracted into hexane and analyzed on a 
Hewlett-Packard 5890 series II gas chromatograph (Wilmington, DE) fitted with a flame-
ionization detector and 3396A integrator. A Supelcowax-10 fused-silica capillary column (60 m 
× 0.32 mm id, 0.25 μM film thickness) was used, and oven temperature was programmed from 
50°C to 200°C, increased 20°C per min, held for 50 min, increased 10°C per min to 220°C, and 
held for 50 min. Fatty acid methyl esters were identified by comparison with standards. 
 
RNA analysis 
Total RNA extraction. Total RNA was isolated using Tri Reagent (Molecular Research Center, 
Inc., Cincinnati, OH) following the manufacturer’s protocol. RNA was extracted with phenol/1-
bromo-3-chloropropane, precipitated with ethanol, dried, and resuspended in H2O. 
Contaminating genomic DNA was removed by treatment with DNase (DNA-free, Ambion). 
 
Relative RT-PCR. Five hundred nanograms from each RNA sample were used for relative 
(semi-quantitative) RT-PCR using the One-Step RT-PCR kit (Qiagen). Multiplex reactions, 
containing gene-specific primer pairs and ribosomal 18S competimer technology internal control 
primer pairs (Ambion), were conducted using a GeneAmp PCR system 9700 (PE Applied 
Biosystems, Foster City, CA). The gene-specific primer pairs used are shown in Table 1. 
Relative levels of mRNA were determined during the exponential phase of amplification, and 
primer-competimer ratios were optimized at the specified cycle numbers. For all samples, first-
strand cDNA was synthesized at 50°C for 30 min, and HotStarTaq DNA polymerase was 
activated following a 15 min incubation at 95°C. PCR running conditions were LPL = 23 cycles 
at 94°C for 30 s, 55°C for 1 min, and 72°C for 30 s; CD-36 = 29 cycles at 94°C for 30 s, 57°C 
for 30 s, and 72°C for 30 s; GLUT4 = 30 cycles at 94°C for 30 s, 57°C for 30 s, and 72°C for 30 
s; aP2 = 22 cycles at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min; and stearoyl-CoA 
desaturase-1 (SCD-1) = 20 cycles at 94°C for 30 s, 57°C for 45 s, and 72°C for 30 s. All 
reactions were followed by a 7 min final extension at 72°C. The PCR products were visualized 
on a 1.5% agarose gel containing ethidium bromide using an Eastman Kodak Digital Science 
Imaging Station (Rochester, NY). 
 
Table 1: Primer sequences used for relative RT-PCR 
Target Gene  Primer Sequence Accession Number 
aP2 sense 5′-GAA ACT TGT CTC CAG TGA AAA C-3′ NM_001442 
 antisense 5′-GGG AGA AAA TTA CTT GCT TG-3′  
LPL sense 5′-GAG ATT TCT CTG TAT GCC ACC-3′ NM_000237 
 antisense 5′-CTG CAA ATG AGA CAC TTT CTC-3′  
CD-36 sense 5′-GAG AAC TGT TAT GGG GCT AT-3′ L06850 
 antisense 5′-TTA AAC TCG AGA GGC AAA GG-3′  
SCD-1 sense 5′-GCT TGT GCC CTG GTA TTT CT-3′ NM_00563 
 antisense 5′-GGA GTG GTG GTA GTT GTG GA-3′  
GLUT4 sense 5′-CTG CGC GTC CAG CTC TTC TAA-3′ NM_001042 
 antisense 5′-GAG GAA GGA GGA AAT CAT GCC-3′  
aP2, adipocyte fatty acid binding protein; CD-36, fatty acid translocase; GLUT4, insulin-dependent glucose transporter 4; LPL, lipoprotein 
lipase; SCD-1, stearoyl-CoA desaturase-1. 
 
Quantitative real-time PCR. First-strand cDNA was synthesized as previously described (61). 
RNA expression was quantified by real-time quantitative PCR using the ABI PRISM 7700 
Sequence Detection System (Applied Biosystems). Each PCR reaction contained, in a final 
volume of 25 μl, 1 μl of first-strand cDNA, 12.5 μl 2× SYBR Green PCR Master Mix (Applied 
Biosystems); and 5 pmol of each primer (Table 2). All reactions were performed using the 
following cycling conditions: 50°C for 2 min, 95°C for 10 min followed by 40 cycles at 95°C for 
15 s, and 60°C for 1 min. PCR was carried out in 96-well plates and in duplicate. Target gene 
mRNA expression was normalized to TATA binding protein mRNA expression and the relative 
amounts of all mRNAs were calculated using the comparative CT method. 
 
Table 2: Primer sequences used for quantitative real-time PCR 
Target Gene  Primer Sequence Accession Number 
ACBP sense 5′-CCC TCA GCC TTG TTT GTA CTG TAT G-3′ NM_020548 
 antisense 5′-TTC GTG TTC CTA GGC AAT GCT-3′  
ACC sense 5′-ATA GCA GAA AAA GTA CGG GCT GA-3′ NM_000664 
 antisense 5′-CAC AAC CCC CAA CAT GGT GT-3′  
aP2 sense 5′-ATA TGA AAG AAG TAG GAG TGG GCT TT-3′ J02874 
 antisense 5′-CCA TGC CAG CCA CTT TCC-3′  
C/EBPα sense 5′-CCC TCA GCC TTG TTT GTA CTG TAT G-3′ U34070 
 antisense 5′-TTC GTG TTC CTA GGC AAT GCT-3′  
GPDH sense 5′-CGA GGT GGC TGA TGA GAA GTT-3′ BC032234 
 antisense 5′-GGG TCC TTG CAG CCA ATG-3′  
HSL sense 5′-AAG TGG GCG CAA GTC CC-3′ NM_005357.2 
 antisense 5′-GCG CAT CGG CTC TGC TAT-3′  
Leptin sense 5′-ACA CGC AGT CAG TCT CCT CCA-3′ NM_000230 
 antisense 5′-GAA TGA AGT CCA AAC CGG TGA-3′  
Perilipin sense 5′-TCA CAG CCA CAT TTC CAT TTG-3′ NM_002606 
 antisense 5′-GTG ACT ATG CAG GTG AAG GCA GTA-3′  
PPARγ1 sense 5′-ATT CTG GCC CAC CAA CTT TG-3′ AY157024 
 antisense 5′-TCC ATT ACG GAG AGA TCC ACG-3′  
PPARγ2 sense 5′-AGC AAA CCC CTA TTC CAT GCT-3′ AY157024 
 antisense 5′-ATC AGT GAA GGA ATC GCT TTC TG-3′  
TBP sense 5′-GCC CAT AGT GAT CTT TGC AGT G-3′ NM_003194 
 antisense antisense5′-AGA AAC CCT TGC GCT GGA A-3′  
ACBP, acyl-CoA binding protein; ACC, acetyl-CoA carboxylase; aP2, adipocyte fatty acid binding protein; C/EBPα, CAAT/enhancer binding 
protein α; GPDH, glycerol-3-phosphate dehydrogenase; HSL, hormone-sensitive lipase; PPARγ, peroxisome proliferator-activated receptor γ; 
TBP, TATA-binding protein. 
 
Immunoblotting 
Cultures were seeded at 4 × 104 cells/cm2 in 35 mm culture plates and allowed to differentiate for 
8, 12, or 16 days in the presence of vehicle or fatty acid treatments. Total cellular protein was 
harvested using PBS (pH 7.5) lysis buffer containing 1% NP40, 0.1% SDS, 0.5% SDS, 30 μl/ml 
aprotinin, 1 mM phenylmethyl-sulfonyl fluoride (PMSF), and 1 mM sodium orthovanadate. The 
samples were incubated on ice with frequent vortexing, centrifuged for 20 min at 15,000 g, and 
stored at −80°C. Protein concentration was determined using the BCA assay. Twenty 
micrograms of total cellular protein was separated by electrophoresis on 4–12% SDS-
polyacrylamide gradient gels (NuPAGE mini-gel system; Invitrogen), transferred to a 
polyvinylidene difluoride membrane using a wet transfer module (Trans-Blot Module; Bio-Rad, 
Inc., Hercules, CA), and prepared for immunodetection. Using a 1:30,000 dilution of a rabbit 
anti-adipocyte fatty acid-binding protein polyclonal primary antibody (generous gift from Dr. D. 
Bernlohr, University of Minnesota) and a 1:1,500 dilution of goat antiperilipin sera (generous 
gift from Dr. C. Londos, NIH-NIDDK) coupled to their respective horseradish peroxidase-
conjugated secondary antibodies, each protein was detected using Western Lightning (PE Life 
Sciences) chemiluminescence substrate. Chemiluminescence was visualized following exposure 
of the membrane to X-ray film (X-OMAT; Eastman Kodak Co.). A signal transducer and 
activator of transcription 6 (sc-981; Santa Cruz Biotech., Santa Cruz, CA) primary antibody was 
used for an internal loading control because it has been validated as a reliable control that is 
constitutively expressed over the adipocyte differentiation program (62, 63). 
 
Transient transfections of 3T3-L1 adipocytes 
Cell culture and differentiation of 3T3-L1 cells. 3T3-L1 cells were cultured in DMEM 
(Invitrogen) containing 4,500 mg/l glucose supplemented with 100 μg/ml streptomycin, 63 μg/ml 
penicillin, 8 μg/ml biotin, and 8 μg/ml pantothenic acid. Standard 3T3-L1 proliferation media 
contained 10% calf serum. Medium was changed every second day. Differentiation of 3T3-L1 
cells was obtained by exposing 2 day postconfluent (designated day 0 cells) to DMEM 
containing 10% FBS (Hyclone, Logan, UT) supplemented with 1 μM dexamethasone, 0.5 mM 
IBMX, and 1 μg/ml insulin (Roche, Basel, Switzerland). At Day 2, cells were fed DMEM 
containing 10% FBS and 1 μg/ml insulin; thereafter the cells were maintained in DMEM and 
10% FBS. 
 
Transient transfections. 3T3-L1 cells were transfected at Day 4 of differentiation using the 
Lipofectamine Plus Reagent procedure (Invitrogen). Transfections were performed in 12-well 
plates with a total of 1 μg DNA per well. Plasmids used in transient transfections were the rat 
acyl-CoA binding protein (ACBP) promoter reporter constructs (pACBP(−392/+979), which 
contains an intronic peroxisome proliferator response element (PPRE)-luc, and 
pACBP(−392/+979)ΔPPRE-luc), in which the PPRE has been mutated (64). The plasmid 
pCMV-β-galactosidase (Clontech, Copenhagen, Denmark) was used for normalization. After 3 h 
of incubation with the DNA mixture, the medium was changed to DMEM containing 10% resin-
charcoal-stripped FBS supplemented with BRL49653 (Novo Nordisk A/S, Copenhagen, 
Denmark) and/or LA, cis-9,trans-11 CLA, trans-10,cis-12 CLA dissolved in DMSO. Cells were 
harvested 24 h later in lysis buffer (Tropix, Copenhagen, Denmark), and the lysates were stored 
at −80°C. All transfections were performed in triplicate. Luciferase and β-galactosidase assays 
were performed as previously described (65). 
 
Statistical analyses 
Data are expressed as the mean ± SEM. Data were analyzed using one-way ANOVA, followed 
by each pair of Student’s t-tests for multiple comparisons. Differences were considered 
significant if P < 0.05. All analyses were performed using JMP IN v4.04 (SAS Institute, Cary, 
NC) software. 
 
RESULTS 
Trans-10,cis-12 CLA decreases lipid accumulation 
In primary cultures of SV cells isolated from human adipose tissue, lipid droplets rich in TG are 
detectable within the first 5 days of differentiation. The amount of ORO staining can be 
quantified spectrophotometrically and parallels the TG content (58). As shown in Fig. 1, 
differentiating preadipocytes treated continuously for 12 days with 30 μM of trans-10,cis-12 
CLA had less stainable TG compared with all other treatments. In contrast, cultures treated with 
LA and cis-9,trans-11 CLA appeared to have more stainable TG than the other treatments. 
 
Trans-10,cis-12 CLA readily incorporates into cellular lipids and reduces the ratio of MUFA-
SFA 
The fatty acid profiles of cellular lipids, especially those of phospholipids, alter signal 
transduction pathways that impact carbohydrate and lipid metabolism. To this end, we examined 
the extent to which trans-10,cis-12 CLA incorporated into neutral and phospholipids fractions 
and its impact on the predominant MUFA and SFA within adipocyte cultures following 12 days 
of continuous treatment during the differentiation program. Trans-10,cis-12 CLA readily 
incorporated into the neutral and phospholipid fractions of the cultures (Table 3). Cultures 
treated with trans-10,cis-12 CLA had consistently less 16:1 and 18:1 in their neutral and 
phospholipid fractions. Cultures treated with trans-10,cis-12 CLA had 35% less 20:4, a precursor 
for eicosanoid synthesis, in the phospholipid fraction than in the controls. The MUFA/SFA ratio 
was lower in cultures treated with 30 μM trans-10,cis-12 CLA compared with vehicle controls. 
In particular, the ratio of 16:1/16:0 was markedly decreased in cultures treated with trans-10,cis 
12 CLA compared with controls (i.e., 5.3- and 11.5-fold lower in the phospholipids and neutral 
lipid fractions, respectively). In keeping with these data, the mRNA level of SCD-1, an enzyme 
that introduces a double bond at position Δ9 in 16:0 and 18:0, was greatly reduced in cultures 
treated with 30 μM trans-10,cis-12 CLA when compared with cultures treated with cis-9,trans-
11 CLA or vehicle (Fig. 2). 
 
Figure 1:  
 
Trans-10,cis-12 conjugated linoleic acid (CLA) decreases lipid accumulation in differentiating human preadipocytes. Cultures were continuously 
treated with either a bovine serum albumin (BSA) vehicle, or 30 μM linoleic acid (LA), cis-9,trans-11 (9,11-CLA), or trans-10,cis-12 (10,12-
CLA) for 12 days during differentiation. On Day 12, cultures were stained with oil red O and phase-contrast photomicrographs were taken using 
an Olympus inverted microscope with a 10× objective. 
 
 
Table 3: Fatty acid composition of phospholipid and neutral lipid cellular fractions of 
differentiating human (pre)adipocytes 
Phospholipid Fraction  Neutral Lipid Fraction 
Fatty Acid BSA CLA  Fatty Acid BSA CLA 
16:0 18.67 ± 1.67 13.98 ± 1.67  16:0 31.35 ± 1.29 11.29 ± 1.45a 
16:1 3.76 ± 0.86 0.50 ± 0.86a  16:1 16.53 ± 0.67 0.42 ± 0.74a 
16:1/16:0 ratio 0.19 ± 0.02 0.04 ± 0.02a  16:1/16:0 ratio 0.53 ± 0.01 0.04 ± 0.01a 
18:0 17.59 ± 0.76 16.37 ± 0.76  18:0 4.01 ± 0.59 8.20 ± 0.66a 
18:1 13.63 ± 0.88 9.88 ± 0.88a  18:1 10.84 ± 0.68 7.46 ± 0.76a 
18:1/18:0 ratio 0.77 ± 0.16 0.61 ± 0.16  18:1/18:0 ratio 2.72 ± 0.12 0.92 ± 0.13a 
18:2 0.83 ± 0.59 1.64 ± 0.59  18:2 ND 1.02 ± 0.51 
20:4 5.90 ± 0.39 3.82 ± 0.39a  20:4 ND 0.53 ± 0.34 
MUFA/SFA ratio 0.47 ± 0.03 0.35 ± 0.03a  MUFA/SFA ratio 0.77 ± 0.02 0.41 ± 0.02a 
t10, c12-CLA ND 8.41 ± 1.11a  t10, c12-CLA ND 19.05 ± 0.96a 
BSA, bovine serum albumin; CLA, conjugated linoleic acid; MUFA, monounsaturated fatty acid; ND, not detectable; SFA, saturated fatty acid. 
Cultures were continuously treated with either a BSA vehicle control of 30 μM trans-10,cis-12 CLA (t10, c12-CLA) for 12 days during 
differentiation. On Day 12, total cellular lipid was extracted and purified into neutral lipid and phospholipid fractions via silica column 
separation. Fatty acid analysis of the resulting fractions was carried out using gas chromatography. Data are g/100 of total fatty acids expressed as 
means ± SEM (n = 5 for neutral lipid, n = 3 for phospholipid). 
aSignificantly different than vehicle control (P < 0.05). 
 
 
 
Figure 2:  
 
Isomer-specific regulation of stearoyl-CoA desaturase-1 (SCD-1) by CLA. The effects of BSA (B), 30 μM cis-9,trans-11 CLA (9), or 30 
μM trans-10,cis-12 CLA (10) on SCD-1 gene expression over the differentiation time course (Days 0, 1, 3, 6, 9, and 12 postinduction) were 
examined using multi-plex semi-quantitative RT-PCR. 18S rRNA was used as an internal control. Results are representative of two separate 
experiments from independent human subjects. 
 
 
Isomer-specific regulation by CLA of glucose uptake and oxidation 
To further investigate potential mechanism(s) by which trans-10,cis-12 CLA decreases de novo 
fatty acid synthesis in human adipocytes (18), we examined isomer-specific effects of CLA on 
glucose uptake and oxidation and GLUT4 expression. Insulin-stimulated [3H]2-deoxy-glucose 
uptake was lower in cultures treated with trans-10,cis-12 CLA compared with all other 
treatments (Fig. 3A). In addition, glucose oxidation as determined by [14C]CO2 production from 
[14C]glucose was lower in cultures treated with 10 μM and 30 μM trans-10,cis-12 CLA 
compared with all other treatments (Fig. 3B). The expression of GLUT4 was significantly lower 
in cultures treated with 30 μM trans-10,cis-12 CLA compared with all other treatments (Fig. 
3C). Collectively, these data suggest that trans-10,cis-12 CLA decreases insulin-stimulated 
glucose uptake and oxidation in differentiating preadipocytes, in part by inhibiting GLUT4 
expression. Thus, in this respect trans-10,cis-12 CLA has an opposite effect of that of PPARγ 
ligands, which increase GLUT4 expression and glucose uptake (66, 67). 
 
Isomer-specific regulation by CLA of fatty acid uptake and utilization 
To determine the extent to which CLA decreased the TG content of the cultures by altering the 
metabolism of exogenously added fatty acids, we examined the effects of CLA on radiolabeled-
fatty acid uptake and utilization. Although all fatty acid treatments decreased [14C]oleic acid 
uptake in a dose-dependent fashion, cultures treated with 30 μM trans-10,cis-12 CLA had the 
lowest rate of fatty acid uptake (~65% of controls) compared with 30 μM cis-9,trans-11 CLA 
(~80% of controls) or 30 μM LA (~85% of controls) (Fig. 4A). 
 
As the level of trans-10,cis-12 CLA increased in the cultures, [14C]oleic acid incorporation into 
lipid- and water-soluble fractions decreased and increased, respectively (Fig. 4B, 4C). In 
contrast, cis-9,trans-11 CLA and LA had only a minor inhibitory effect on [14C]oleic acid 
incorporation into lipid and did not affect the incorporation into the water-soluble fraction (Fig. 
4B, C). 
 
Furthermore, addition of increasing concentrations of CLA isomers and LA decreased fatty acid 
oxidation, as determined by [14C]CO2 production from [14C]oleic acid (Fig. 4D). However, 
cultures treated with 10 μM and 30 μM trans-10,cis-12 CLA had less [14C]CO2 produced from 
[14C]oleic acid (e.g., ~55% and 40% of control cells, respectively) compared with equimolar 
concentrations of cis-9,trans-11 CLA (e.g., ~90% and 65% of control cells, respectively) and LA 
(e.g., ~85% and 65% of control cells, respectively). 
 
Parallel experiments showed that the expressions of LPL and aP2 (Fig. 4E, F, respectively) were 
significantly decreased in cultures treated for 6 days with 30 μM trans-10,cis-12 CLA compared 
with all other treatments. By contrast, the expression of CD-36 (Fig. 4G), a plasma membrane 
translocase involved in fatty acid transport, was only slightly decreased by trans-10,cis-12 CLA 
(e.g., ~80% and ~70% of controls, after 9 days and 12 days of treatment, respectively). In 
summary, these results show that the trans-10,cis-12 CLA isomer specifically decreases fatty 
acid uptake and esterification as well as oxidation of these exogenously derived fatty acids. 
 
Figure 3:  
 
Isomer-specific regulation of human adipocyte glucose metabolism by CLA. Cultures of differentiating human preadipocytes were continuously 
treated with increasing concentrations (0, 3, 10, or 30 μM) of either LA (diamond), cis-9, trans-11 CLA (square), or trans-10, cis-12 CLA 
(triangle) for 12 days during differentiation. A: Uptake of 4 nmol [3H]2-deoxy-glucose (specific activity = 25–50 Ci/mmol) was measured 
following a 90 min incubation in the presence of 100 nm insulin; control rate was 146 pmol/[h · mg protein]. B: [14C]CO2 production from 
[14C]glucose was measured following a 5 h incubation with 2.2 nmol [14C]glucose (specific activity = 231 mCi/mmol) in the presence of 100 nm 
insulin; control rate was 15 pmol/[h · mg protein]. For A and B, data are expressed as a percentage of vehicle control (BSA) levels. Means 
(±SEM; n = 6) not sharing a common superscript differ, P < 0.05. C: In addition, the effects of BSA (B), 30 μM cis-9,trans-11 CLA (9) or 30 
μM trans-10,cis-12 CLA (10) on insulin-dependent glucose transporter 4 (GLUT4) gene expression over the differentiation time course (Days 0, 
1, 3, 6, 9, and 12 postinduction) was conducted using multiplex semi-quantitative RT-PCR. 18S rRNA was used as an internal control. Results for 
GLUT4 expression are representative of two separate experiments from independent human subjects. 
Figure 4: 
 
Isomer-specific regulation of human adipocyte lipid metabolism by CLA. Cultures of differentiating human preadipocytes were continuously 
treated with increasing concentrations (0, 3, 10, or 30 μM) of either LA (diamond), cis-9,trans-11 CLA (square), or trans-10,cis-12 CLA 
(triangle) for 6 days during differentiation. On Day 6, [14C]oleic acid metabolism was measured by determining the incorporation of the 
radionuclide into distinct cellular and gaseous fractions. A: [14C]oleic acid (6.2 nmol) uptake after 20 min incubation; control rate was 38.1 
nmol/(h · mg protein). B: [14C]oleic acid (12.5 nmol) incorporation into the lipid-soluble cellular fraction after 2 h incubation; control rate was 5.3 
nmol/(h · mg protein). C: [14C]oleic acid (12.5 nmol) incorporation into the water-soluble cellular fraction after 2 h incubation; control rate was 
53.4 pmol/(h · mg protein). D: [14C]CO2 production from [14C]oleic acid following 90 min incubation with 12.5 nmol [14C]oleic acid; control rate 
was 100 pmol/(h · mg protein). For A–D, data are expressed as a percentage of vehicle control (BSA) levels. Means (±SEM; n = 6) not sharing a 
common superscript differ, P < 0.05. In addition, the effects of BSA (B), 30 μM cis-9,trans-11 CLA (9), or 30 μM trans-10,cis-12 CLA (10) on 
lipoprotein lipase (LPL) (E), adipocyte fatty acid binding protein (aP2) (F), and fatty acid translocase (CD-36) (G) gene expression over the 
differentiation time course (Days 0, 1, 3, 6, 9, and 12 postinduction) were examined using multiplex semi-quantitative RT-PCR. 18S rRNA was 
used as an internal control. Results for LPL, aP2, and cd36 are representative of two separate experiments from independent human subjects. 
 
 
Isomer-specific regulation by CLA of gene expression in adipocytes 
To determine the extent to which CLA’s suppression of lipid metabolism was due to suppressing 
the differentiation program, we examined the isomer-specific impact of CLA on the expression 
of genes involved in preadipocyte differentiation, including the master regulator of adipocyte 
differentiation, PPARγ, and several genes known to be positively regulated by PPARγ such as 
LPL, aP2, and ACBP, (53, 54, 64). The expressions of several other adipocyte genes such as 
C/EBPα, glycerol dehydrogenase (GPDH), hormone-sensitive lipase (HSL), leptin, perilipin, and 
acetyl-CoA carboxylase (ACC) were also determined. The time courses of expression of these 
genes are shown in Fig. 5A. With the exception of leptin, gene expressions paralleled that of 
PPARγ and peaked on Day 3 of the differentiation program (Fig. 5A). 
 
Figure 5: 
 
Time course and CLA-induced alterations of human adipocyte gene expression. A: For the time course data, confluent cultures of human 
preadipocytes were induced to differentiate under standard adipogenic conditions, and total RNA was harvested throughout adipose conversion 
(Day 0, 8 h, 24 h, 72 h, and 216 h postinduction). Total RNA was used for first-strand cDNA synthesis, and real-time quantitative RT-PCR 
analyses were performed to analyze the expression of acyl-CoA binding protein (ACBP), adipocyte fatty acid binding protein (aP2), 
CAAT/enhancer binding protein α (C/EBPα), glycerol dehydrogenase (GPDH), hormone-sensitive lipase (HSL), perilipin, peroxisome 
proliferator-activated receptors γ1 and γ2 (PPARγ1 and PPARγ2), leptin, and acetyl-CoA carboxylase (ACC). The relative expression level of a 
given gene was calculated after normalization to TATA-binding protein expression, and was expressed relative to Day 0 (confluent, noninduced) 
controls. B: To examine the effects of fatty acid treatment on gene expression, cultures were continuously treated with either a BSA vehicle 
control, 30 μM cis-9,trans-11 CLA (9, 11), or 30 μM trans-10,cis-12 CLA (10, 12) for either 0 h, 8 h, 24 h, 72 h, or 216 h during differentiation. 
Real-time quantitative RT-PCR analyses were performed as stated above to analyze gene expression. Results shown are only for the 216 h 
treatments and are representative of three separate experiments from independent human subjects. 
 
 
CLA treatment had no impact on gene expressions after 8 h, 24 h, or 72 h of treatment, i.e., 
during the time of treatment with the PPARγ ligand BRL49653. However, after 9 days of 
treatment with trans-10,cis-12 CLA, the expression of PPARγ1 and PPARγ2, as well as known 
PPARγ target genes (e.g., ACBP, aP2, and perilipin-A), was markedly reduced compared with 
that of control cultures (Fig. 5B). The CLA-mediated down-regulation of aP2 and perilipin-A 
were also reflected in drastic reductions of their respective protein levels (Fig. 6A), which could 
not be rescued by cosupplementation with LA (Fig. 6B). In addition, the levels of mRNA for 
C/EBPα, GPDH, HSL, and ACC were dramatically lower in cultures treated with trans-10,cis-12 
CLA compared with the other treatments (Fig. 5B). In contrast, cis-9,trans-11 CLA increased the 
expression of most of these genes. Interestingly, the expression of leptin was increased in 
cultures treated with trans-10,cis-12 CLA compared with controls, whereas cis-9,trans-11 CLA 
had no effect. Taken together, these results show that the effect of the trans-10,cis-12 CLA 
isomer is not simply a general down-regulation of all adipocyte-specific genes. 
 
Figure 6: 
 
Isomer-specific down-regulation of adipocyte fatty acid binding protein (aP2) and perilipin protein levels by CLA are not rescued by LA 
supplementation. Western blot analyses of perilipin A and aP2 proteins were conducted in differentiating human preadipocytes under the 
following treatment conditions: A: Cultures were continuously treated with either a BSA vehicle control or 30 μM LA, cis-9,trans-11 CLA (9, 
11), or trans-10,cis-12 CLA (10, 12), and total cellular protein was harvested on Day 8 (d8) and Day 16 (d16) of differentiation. B: Cultures were 
treated continuously with either a vehicle control (BSA), 30 μM trans-10,cis-12 CLA alone (CLA), or 30 μM trans-10,cis-12 CLA plus 
increasing levels (10 μM, 30 μM, or 100 μM) of LA (CLA + 10 LA, CLA + 30 LA, CLA + 100 LA), or increasing levels of LA alone (10 μM 
LA, 30 μM LA, 100 μM LA), and total cellular protein was harvested on Day 12 of differentiation. The abundant protein signal transducer and 
activator of transcription six was used as a loading control. 
 
 
CLA antagonizes ligand-dependent activation of PPARγ 
We demonstrated that trans-10,cis-12 CLA decreased the expression of genes influencing 
differentiation, including those regulated by PPARγ, and PPARγ expression itself. Since CLA 
isomers have been shown to activate PPARγ with very low efficacy (55, 56), it is possible that 
CLA directly affects PPARγ activity by competing with endogenous ligands with higher 
efficacy. To investigate this hypothesis, we transiently transfected 3T3-L1 adipocytes with a 
reporter construct containing the proximal promoter and intron 1 of the rat ACBP gene. We have 
recently identified a PPRE located in intron 1 of this gene, and have shown that it efficiently 
mediates transactivation by endogenous PPARγ in 3T3-L1 adipocytes (64). In the absence of an 
exogenously added PPARγ ligand, both isomers of CLA slightly decreased reporter activity (Fig. 
7). Furthermore, when 0.1 μM BRL 49653 was added along with CLA to the cultures, both 
isomers antagonized the ligand-dependent activation of the reporter construct, with trans-10,cis-
12 CLA being the most robust antagonist. Importantly, neither BRL49653 nor CLA isomers 
affected the activity of the reporter construct when the PPRE was mutated. These data show that 
both CLA isomers are indeed able to directly antagonize PPARγ activity. 
 
Figure 7: 
 
Acute effect of CLA isomers on PPARγ activity in 3T3-L1 adipocytes. 3T3-L1 adipocytes (Day 4 after induction of differentiation) were 
transiently transfected with (A) the ACBP (−392/+979)-luc constructs containing the rat ACBP proximal promoter and intron 1 or (B) the 
rACBP(−392/+979)-Δ-peroxisome proliferator response element (PPRE)-luc reporter where the intronic PPRE has been mutated. Cells were 
transfected using LipofectAMINE PLUS, and 3 h later media was changed and fatty acids and/or BRL49653 were added as indicated. LA, cis-
9,trans-11 CLA, or trans-10,cis-12 CLA were added to final concentrations of 0.1 μM, 0.3 μM, 1 μM, or 30 μM. Cells were harvested after 24 h 
and luciferase activity was measured and normalized to β-galactosidase activity. 
 
 
DISCUSSION 
To our knowledge, this is the first study to provide insights regarding the differential effects of 
trans-10,cis-12 and cis-9,trans-11 CLA on glucose and lipid metabolism and markers of 
differentiation in primary cultures of human preadipocytes. We have previously demonstrated 
that the trans-10,cis-12 isomer of CLA reduces de novo fatty acid synthesis from [14C]glucose 
when compared with vehicle- or cis-9,trans-11 CLA-treated cultures of human preadipocytes 
(18). In this study, we show that trans-10,cis-12 CLA dose-dependently reduced insulin-
stimulated uptake (Fig. 3A) and oxidation (Fig. 3B) of glucose in differentiating cultures of 
human preadipocytes. The reduction in facilitated uptake was paralleled by a dramatic reduction 
in GLUT4 mRNA (Fig. 3C). In addition, our data demonstrate that the trans-10,cis-12 isomer of 
CLA represses the uptake, incorporation into lipid, and oxidation to CO2 of oleic acid when 
compared with all other treatments (Fig. 4A, B, D) in human adipocytes. 
 
Although trans-10,cis-12 CLA reduced glucose uptake in cultures of differentiating human 
adipocytes, this is not likely the main TG-lowering mechanism of trans-10,cis-12 CLA, because 
de novo fatty acid synthesis is not robust in preadipocytes isolated from humans compared with 
preadipocytes from other mammals (68). In contrast, fatty acids delivered by lipoproteins or 
albumin contribute significantly to the cellular TG pool of human adipocytes (68). In support of 
this concept, we found that only 0.9% of the total radiolabeled glucose that got into control cells 
was recovered in the lipid-soluble fraction. In contrast, 96% of the sequestered [14C]oleic acid 
was recovered in the lipid-soluble fraction in nontreated control cultures. Furthermore, the rate of 
oxidation of [14C]oleic acid to [14C]CO2 (~100 pmol/[h ··mg protein]) was 6-fold higher than 
[14C]glucose to [14C]CO2 (~15 pmol/[h · mg protein]) in vehicle treated cultures. In addition, the 
rate of [14C]oleic acid uptake (38 nmol/[h · mg protein]) was ~260-fold greater than the rate of 
insulin-stimulated uptake of [3H]2-deoxy-glucose (146 pmol/[h · mg protein]). Collectively, 
these data show that primary cultures of differentiating human preadipocytes utilize [14C]oleic 
acid much more readily than [14C]glucose for energy production and storage, and it is likely that 
intra-cellular TG pools are derived mainly from preformed fatty acids compared with de novo 
fatty acid synthesis. 
 
In this work, we have addressed the mechanism by which trans-10,cis-12 CLA decreased 
glucose and fatty acid uptake and incorporation into cellular lipids by investigating the effect of 
CLA isomers on the mRNA expression of a number of adipocyte genes. Our data clearly show 
that the CLA isomers have little effect on adipocyte gene expression during the first 3 days after 
induction of differentiation when the PPARγ agonist BRL49653 is present in the cell culture 
medium. By contrast, chronic treatment with trans-10,cis-12 CLA until Day 9 significantly 
reduces the expression of several adipocyte-specific genes, including PPARγ and PPARγ target 
genes (Fig. 5B), whereas cis-9,trans-11 CLA treatment increases PPARγ-dependent gene 
expression. As PPARγ is a key transcription factor in the induction of adipogenesis and lipid 
accumulation, this isomer-specific down-regulation of PPARγ expression is likely to explain at 
least part of the observed effects of trans-10,cis-12 CLA on glucose and lipid metabolism. 
 
In addition, since PPARγ activity is regulated by fatty acid ligands (46, 48, 53), and since the 
CLA isomers have been reported to be weak agonists of PPARγ (55, 56), we speculated that the 
CLA isomers might act as partial agonists of PPARγ, thereby antagonizing PPARγ activity by 
competing with endogenous ligands with higher efficacy. To investigate this hypothesis, we 
transiently transfected mature 3T3-L1 adipocytes with PPAR-responsive constructs. Our results 
show that both CLA isomers can directly antagonize both basal PPARγ activity (i.e., the activity 
dependent on endogenous ligands) as well as transcriptional activity induced by suboptimal 
concentrations of BRL49653 in murine adipocytes (Fig. 7). Although the trans-10,cis-12 CLA 
isomer is slightly more effective than the cis-9,trans-11 CLA isomer, lack of strict isomer 
specificity indicates that direct antagonism is unlikely to contribute significantly to the 
antiadipogenic effects of trans-10,cis-12 CLA. It remains possible that long-term treatment, as 
opposed to the short-term treatment in transient transfections, with trans-10,cis-12 CLA 
interferes with the synthesis of endogenous PPARγ ligands in human preadipocytes, thereby 
down-regulating PPARγ activity. For example, the 35% decrease in 20:4 in the phospholipid 
fraction induced by trans-10,cis-12 CLA treatment might reduce the synthesis of prostaglandins 
activating PPARγ. However, so far our results support a model in which the trans-10,cis-12 CLA 
isomer specifically down-regulates the expression of PPARγ, and thereby decreases both 
lipogenesis and adipogenesis. 
 
Along with the PPARγ-dependent effects of CLA on glucose and lipid metabolism, our work 
suggests that the CLA isomers might also directly interfere with cellular enzyme activity. In this 
work, we show that trans-10,cis-12 CLA was incorporated into cellular neutral lipids and 
phospholipids (Table 3) and can thereby possibly alter membrane fluidity and/or signal 
transduction. Furthermore, in keeping with other reports, trans-10,cis-12 CLA dramatically 
reduced the MUFA/SFA ratio in differentiating cultures of human preadipocytes, specifically 
16:1/16:0 (Table 3). It is probable that this shift in fatty acid profile is due to decreased 
expression or activity of SCD-1 (69–71), as previously reported by Ntambi and others (21, 22, 
25). In agreement with this hypothesis, we found that mRNA levels of SCD-1 in cultures treated 
with 30 μM trans-10,cis-12 CLA on Days 6 and 9 of differentiation were 33% and 18% of 
control levels, respectively (Fig. 2). Since oleate is the preferred substrate for TG synthesis, the 
decrease in MUFA is likely to decrease TG accumulation independent of the expression of the 
respective enzymes involved. Furthermore, we observed a 100% increase in 18:0 in the neutral 
lipid fraction. This CLA-mediated increase in 18:0 could negatively feed back on the activity and 
expression of ACC (Fig. 5B), and subsequently decrease de novo fatty acid lipogenesis, as we 
have previously demonstrated (18). 
 
Finally, trans-10,cis-12 CLA increased the incorporation of [14C]oleic acid into the water-soluble 
cellular fraction when compared with all other treatments (Fig. 4C). Interestingly, a recent report 
demonstrated that CLA isomers were poorly oxidized and accumulated as carnitine and acyl-
CoA esters, which would partition to the water-soluble cellular fraction (72). Therefore, trans-
10,cis-12 CLA may interfere with β-oxidation, resulting in an accumulation of thioesters of fatty 
acids. 
 
Based on our data, it is tempting to speculate that the unresolved effects of CLA in human 
supplementation studies are due to the inclusion of cis-9,trans-11 CLA in the crude mixture. Our 
data suggest that the trans-10,cis-12 isomer of CLA is indeed antiadipogenic in differentiating 
human preadipocytes, whereas the cis-9,trans-11 isomer promotes adipogenesis. Therefore, 
when given together as an isomeric mixture, the antagonistic roles of cis-9,trans-11 CLA and 
trans-10,cis-12 CLA may negate one another, resulting in no change in adiposity. In support of 
this concept, Riserus et al. (43) found that obese subjects receiving 3.4 g/day of trans-10,cis-12 
CLA for 12 weeks weighed less, had smaller girths, and had lower BMIs compared with baseline 
measurements. In contrast, the weight, girth, and BMI of subjects receiving 3.4 g/day of a crude 
mixture of cis-9,trans-11 and trans-10,cis-12 CLA for 12 week were similar to baseline. 
 
In summary, our data suggest that physiological levels (e.g., 10–30 μM) of trans-10,cis-12 CLA 
can act as an anti-adipogenic nutrient in differentiating human preadipocytes. However, this 
effect is highly isomer specific, and previous work by our group (18) has demonstrated that the 
level used is critical in eliciting a TG-lowering effect. It is likely that the trans-10,cis-12 isomer 
of CLA reduces TG accumulation in differentiating preadipocytes by reducing fatty acid uptake 
and altering fatty acid metabolism in a way that favors less oxidation, desaturation, and 
esterification of long-chain fatty acids. Furthermore, the trans-10,cis-12 isomer of CLA 
dramatically inhibited insulin-stimulated glucose uptake and oxidation, which was coupled to 
decreased expression of GLUT4. These effects on fatty acid and glucose uptake and metabolism 
are likely downstream effects of the ability of trans-10,cis-12 isomers of CLA to decrease 
PPARγ expression or to antagonize PPARγ-dependent activation of genes directly or indirectly 
involved in these metabolic processes. Our results show that both CLA isomers antagonize 
PPARγ activity, indicating that direct antagonism cannot explain the isomer specific effects of 
trans-10,cis-12 CLA. 
 
Collectively, these trans-10,cis-12 CLA-induced metabolic perturbations are indeed 
antiadipogenic, but may have deleterious effects in vivo, because down-regulation of PPARγ 
may lead to insulin resistance, hyperglycemia, and hyperlipidemia. Therefore, it is imperative 
that future studies identify isomer-specific responses, and consider the safety and efficacy of 
dietary supplementation in human populations. It is entirely possible that proper isomer-specific 
dose titrations may prove beneficial, but more research is needed to fully understand the 
molecular mechanism by which CLA is exerting its antiobesity effects before we can be sure. 
 
ABBREVIATIONS 
ACBP, acyl-CoA binding protein; ACC, acetyl-CoA carboxylase; aP2/FABP, adipocyte fatty 
acid binding protein; BCA, bicinchoninic acid; BMI, body mass index; BSA, bovine serum 
albumin; CD-36, fatty acid translocase; C/EBPα, CAAT/enhancer binding protein α; CLA, 
conjugated linoleic acid; GC, gas chromatography; GLUT4, insulin-dependent glucose 
transporter 4; GPDH, glycerol-3-phosphate dehydrogenase; HSL, hormone-sensitive lipase; 
IBMX, isobutylmethylxanthine; LA, linoleic acid; LPL, lipoprotein lipase; MUFA, 
monounsaturated fatty acid; ORO, oil red O; PPAR, peroxisome proliferator-activated receptor; 
PPRE, peroxisome proliferator response element; SCD-1, stearoyl-CoA desaturase-1; SFA, 
saturated fatty acid; SV, stromal vascular; TG, triglyceride 
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